董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Dawn C. Bir | 女 | Director | 54 | 12.92万美元 | 未持股 | 2025-10-15 |
| Elizabeth G. O'Farrell | 女 | Chairman | 60 | 13.67万美元 | 未持股 | 2025-10-15 |
| Harout Semerjian | 男 | President and Chief Executive Officer and Director | 54 | 未披露 | 未持股 | 2025-10-15 |
| John F. McDonald | -- | Independent Director | -- | 未披露 | 未持股 | 2025-10-15 |
| Robert J. Spiegel | 男 | Independent Director | 75 | 13.92万美元 | 未持股 | 2025-10-15 |
| V. Bryan Lawlis | 男 | Independent Director | 73 | 14.42万美元 | 未持股 | 2025-10-15 |
| Susan M. Molineaux | 女 | Independent Director | 71 | 13.42万美元 | 未持股 | 2025-10-15 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Harout Semerjian | 男 | President and Chief Executive Officer and Director | 54 | 未披露 | 未持股 | 2025-10-15 |
| Shannon T. Odam | -- | Senior Vice President and Chief People Officer | -- | 未披露 | 未持股 | 2025-10-15 |
| Michelle J. Robertson | -- | Executive Vice President, Finance, Chief Financial Officer, Principal Accounting Officer and Treasurer | -- | 未披露 | 未持股 | 2025-10-15 |
| Scott A. Samuels | -- | Executive Vice President, Chief Legal Officer and Corporate Secretary | -- | 未披露 | 未持股 | 2025-10-15 |
| Edward E. Koval | -- | Executive Vice President and Chief Business Officer | -- | 未披露 | 未持股 | 2025-10-15 |
| Faye Feller | -- | Executive Vice President and Chief Medical Officer | -- | 未披露 | 未持股 | 2025-10-15 |
| Joseph Emile Eid | -- | Executive Vice President, Research and Development | -- | 未披露 | 未持股 | 2025-10-15 |
| Melissa A. Kelly Behrs | 女 | Executive Vice President, Business Operations and Chief Alliance Officer | 61 | 100.75万美元 | 未持股 | 2025-10-15 |
董事简历
中英对照 | 中文 | 英文- Dawn C. Bir
-
Dawn C. Bir，自2019年3月起担任Geron的董事。自2016年9月起，她担任Reata Pharmaceuticals, Inc.（一家生物制药公司）的首席商务官，在那里她领导营销、市场准入、销售和商业运营。从2013年2月到2016年9月，Bir女士担任Pharmacyclics LLC （AbbVie公司）的销售副总裁，在那里她建立并领导他们的第一个血液学全国销售组织，并负责IMBRUVICA在美国和波多黎各的推出。女士从2011年10月到2013年2月Bir担任销售和营销的副总裁天空制药包装有限公司& Rx Pak，单位在美国制药McKesson分工和专业解决方案公司，全球医疗保健公司，在那里她负责两家公司和收入中心，并领导多个职能，包括销售、市场营销、合同管理、项目管理和客户服务。从1996年到2011年10月，她担任Genentech, Inc.（罗氏集团（全球制药公司）的成员）和Bristol-Myers Squibb company（全球制药公司）的几个商业和销售职位，并不断被提拔。她持有宾厄姆顿大学（Binghamton University）生物学学士学位。
Dawn C. Bir has served as a director of Geron since March 2019. Since September 2016 Ms. Bir has served as the Chief Commercial Officer of Reata Pharmaceuticals, Inc., a biopharmaceutical company, where she leads marketing, market access, sales, and commercial operations. From February 2013 to September 2016 Ms. Bir served as Vice President of Sales with Pharmacyclics LLC, an AbbVie company, where she built and led their first hematology national sales organization, and was responsible for the launch of IMBRUVICA in the United States and Puerto Rico. From October 2011 to February 2013 Ms. Bir served as Vice President of Sales & Marketing of SKY Pharmaceuticals Packaging, Inc. & Rx Pak, a unit within the U.S. pharmaceutical and specialty solutions division of McKesson Corporation, a global healthcare company, where she was responsible for two companies and revenue centers, and led multiple functions, including sales, marketing, contract management, project management and customer service. From 1996 to October 2011 Ms. Bir held several commercial and sales positions of increasing responsibility within Genentech, Inc., a member of the Roche Group, a global pharmaceutical company, and Bristol-Myers Squibb Company, a global pharmaceutical company. Ms. Bir holds a B.S. in Biology from Binghamton University. - Dawn C. Bir，自2019年3月起担任Geron的董事。自2016年9月起，她担任Reata Pharmaceuticals, Inc.（一家生物制药公司）的首席商务官，在那里她领导营销、市场准入、销售和商业运营。从2013年2月到2016年9月，Bir女士担任Pharmacyclics LLC （AbbVie公司）的销售副总裁，在那里她建立并领导他们的第一个血液学全国销售组织，并负责IMBRUVICA在美国和波多黎各的推出。女士从2011年10月到2013年2月Bir担任销售和营销的副总裁天空制药包装有限公司& Rx Pak，单位在美国制药McKesson分工和专业解决方案公司，全球医疗保健公司，在那里她负责两家公司和收入中心，并领导多个职能，包括销售、市场营销、合同管理、项目管理和客户服务。从1996年到2011年10月，她担任Genentech, Inc.（罗氏集团（全球制药公司）的成员）和Bristol-Myers Squibb company（全球制药公司）的几个商业和销售职位，并不断被提拔。她持有宾厄姆顿大学（Binghamton University）生物学学士学位。
- Dawn C. Bir has served as a director of Geron since March 2019. Since September 2016 Ms. Bir has served as the Chief Commercial Officer of Reata Pharmaceuticals, Inc., a biopharmaceutical company, where she leads marketing, market access, sales, and commercial operations. From February 2013 to September 2016 Ms. Bir served as Vice President of Sales with Pharmacyclics LLC, an AbbVie company, where she built and led their first hematology national sales organization, and was responsible for the launch of IMBRUVICA in the United States and Puerto Rico. From October 2011 to February 2013 Ms. Bir served as Vice President of Sales & Marketing of SKY Pharmaceuticals Packaging, Inc. & Rx Pak, a unit within the U.S. pharmaceutical and specialty solutions division of McKesson Corporation, a global healthcare company, where she was responsible for two companies and revenue centers, and led multiple functions, including sales, marketing, contract management, project management and customer service. From 1996 to October 2011 Ms. Bir held several commercial and sales positions of increasing responsibility within Genentech, Inc., a member of the Roche Group, a global pharmaceutical company, and Bristol-Myers Squibb Company, a global pharmaceutical company. Ms. Bir holds a B.S. in Biology from Binghamton University.
- Elizabeth G. O'Farrell
-
Elizabeth G. O'Farrell自2019年3月起担任Geron董事。Farrell女士自2020年12月起担任Inhibikase Therapeutics（一家创新小分子激酶抑制剂疗法以治疗神经感染和神经退行性疾病的制药公司）和LENSAR，Inc.（一家全球医疗技术公司）董事会成员，自2021年1月起。2017年12月，Farrell女士从礼来公司（Eli Lilly and Company）离开。礼来公司是一家全球性制药公司，在礼来公司担任了24年的职业生涯，她曾担任财务和公司治理方面的多个高级管理职位，最近一次担任首席采购官和全球共享服务主管，任期为2012年1月至2017年12月份。在此之前，她还担任政策和财务高级副总裁；财务高级副总裁；礼来美国首席财务官；礼来加拿大公司首席财务官；和总审计师。在加入礼来之前，Farrell女士是Boise Cascade Office Products的会计师，并在专业会计师事务所Whipple&Company和国际公共会计师事务所Price Waterhouse担任审计师。Farrell女士拥有印第安纳大学荣誉会计学士学位和管理信息系统硕士学位。
Elizabeth G. O'Farrell has served as a director of Geron since March 2019. Ms. O'Farrell also serves as a member of the board of directors of Inhibikase Therapeutics, a pharmaceutical company innovating small-molecule kinase inhibitor therapeutics for treatment of neurological infections and neurodegenerative diseases, since December 2020 and LENSAR, Inc., a global medical technology company, since January 2021. In December 2017 Ms. O'Farrell retired from a 24-year career with Eli Lilly and Company, a global pharmaceutical company, where she held several senior management positions in finance and corporate governance, most recently serving as Chief Procurement Officer and Head of Global Shared Services from January 2012 to December 2017. Prior to that position, she also served as Senior Vice President, Policy and Finance; Senior Vice President, Finance; Chief Financial Officer, Lilly USA; Chief Financial Officer, Lilly Canada; and General Auditor. Before joining Eli Lilly, Ms. O'Farrell was an accountant with Boise Cascade Office Products, and served as an auditor at Whipple & Company, a professional accountancy firm, and Price Waterhouse, an international public accounting firm. Ms. O'Farrell holds a B.S. in accounting with honors and an M.B.A. in management information systems, both from Indiana University. - Elizabeth G. O'Farrell自2019年3月起担任Geron董事。Farrell女士自2020年12月起担任Inhibikase Therapeutics（一家创新小分子激酶抑制剂疗法以治疗神经感染和神经退行性疾病的制药公司）和LENSAR，Inc.（一家全球医疗技术公司）董事会成员，自2021年1月起。2017年12月，Farrell女士从礼来公司（Eli Lilly and Company）离开。礼来公司是一家全球性制药公司，在礼来公司担任了24年的职业生涯，她曾担任财务和公司治理方面的多个高级管理职位，最近一次担任首席采购官和全球共享服务主管，任期为2012年1月至2017年12月份。在此之前，她还担任政策和财务高级副总裁；财务高级副总裁；礼来美国首席财务官；礼来加拿大公司首席财务官；和总审计师。在加入礼来之前，Farrell女士是Boise Cascade Office Products的会计师，并在专业会计师事务所Whipple&Company和国际公共会计师事务所Price Waterhouse担任审计师。Farrell女士拥有印第安纳大学荣誉会计学士学位和管理信息系统硕士学位。
- Elizabeth G. O'Farrell has served as a director of Geron since March 2019. Ms. O'Farrell also serves as a member of the board of directors of Inhibikase Therapeutics, a pharmaceutical company innovating small-molecule kinase inhibitor therapeutics for treatment of neurological infections and neurodegenerative diseases, since December 2020 and LENSAR, Inc., a global medical technology company, since January 2021. In December 2017 Ms. O'Farrell retired from a 24-year career with Eli Lilly and Company, a global pharmaceutical company, where she held several senior management positions in finance and corporate governance, most recently serving as Chief Procurement Officer and Head of Global Shared Services from January 2012 to December 2017. Prior to that position, she also served as Senior Vice President, Policy and Finance; Senior Vice President, Finance; Chief Financial Officer, Lilly USA; Chief Financial Officer, Lilly Canada; and General Auditor. Before joining Eli Lilly, Ms. O'Farrell was an accountant with Boise Cascade Office Products, and served as an auditor at Whipple & Company, a professional accountancy firm, and Price Waterhouse, an international public accounting firm. Ms. O'Farrell holds a B.S. in accounting with honors and an M.B.A. in management information systems, both from Indiana University.
- Harout Semerjian
-
Harout Semerjian，最近于2021年8月至2025年2月担任GlycoMimetics，Inc.的总裁兼首席执行官，该公司是一家后期临床生物技术公司，随后与Crescent Biopharma，Inc.合并。他此前还曾在GlycoMimetics的董事会任职。自2023年10月起，Semerjian先生还担任生物技术创新组织的董事会成员。2020年6月至2021年7月，Semerjian先生在Emerge Bio Consulting担任独立的医疗保健顾问，就医疗保健投资项目为私募股权公司提供咨询。Semerjian先生曾担任Immunomedics Inc.的总裁兼首席执行官，该公司是一家专注于癌症治疗的抗体-药物偶联物的生物技术公司。在2018年3月至2020年4月被吉利德科学公司收购之前，从2020年4月至2020年5月，Semerjian先生曾担任IPSEN Pharma的执行副总裁兼首席商务官，该公司是一家全球性制药公司，专注于高度未满足的医疗需求领域，领导和执行IPSEN的全球商业战略和跨肿瘤学、神经科学和罕见疾病的职能。2017年2月至2018年2月，担任易卜生专科护理国际区域和全球特许经营权总裁兼负责人。从1994年到2017年1月，Semerjian先生在全球制药公司诺华制药担任过多个商业、营销和销售职位，责任越来越大，包括担任KISQALI的高级副总裁和全球发布负责人，在美国、中东和北非和北欧担任区域副总裁血液学和肿瘤学职务，并担任格列卫全球品牌总监，以及全球性制药公司默沙东和跨国化工与材料公司索尔维。Semerjian先生拥有加拿大康奈尔大学和皇后大学的MBA学位，以及黎巴嫩美国大学的生物学学士学位。董事会认为，Semerjian先生深厚的商业和血液学专业知识、广泛的领导经验和全球视野使他有资格担任董事会成员。
Harout Semerjian,most recently served as President and Chief Executive Officer of GlycoMimetics, Inc., a late-stage clinical biotechnology company subsequently combined with Crescent Biopharma, Inc., from August 2021 until February 2025. He also previously served on the board of directors of GlycoMimetics. Since October 2023, Mr. Semerjian has also served as a member of the board of directors at the Biotechnology Innovation Organization. From June 2020 to July 2021, Mr. Semerjian served as an independent healthcare consultant at Emerge Bio Consulting, advising private equity firms on healthcare investment projects. Mr. Semerjian served as President and Chief Executive Officer of Immunomedics Inc., a biotechnology company specializing in antibody-drug conjugates for cancer treatment, from April 2020 to May 2020, prior to its acquisition by Gilead Sciences, Inc. From March 2018 to April 2020, Mr. Semerjian served as Executive Vice President, Chief Commercial Officer of Ipsen Pharma, a global, pharmaceutical company focusing on areas of high unmet medical need, leading and executing Ipsen's global commercial strategy and functions across oncology, neurosciences and rare diseases. From February 2017 to February 2018, he served as President and Head of Ipsen's Specialty Care International Region & Global Franchises. From 1994 to January 2017, Mr. Semerjian held several commercial, marketing and sales positions of increasing responsibility within Novartis Pharmaceuticals, a global pharmaceutical company, including serving as Senior Vice President and Global Launch Leader for KISQALI, in regional vice president hematology and oncology roles in the U.S., MENA and the Nordics, and as global brand director for Gleevec, as well as for Merck, a global pharmaceutical company, and Solvay, a multinational chemical and materials company. Mr. Semerjian holds an MBA from Cornell University and Queen's University in Canada, and a B.S. in Biology from Lebanese American University. - Harout Semerjian，最近于2021年8月至2025年2月担任GlycoMimetics，Inc.的总裁兼首席执行官，该公司是一家后期临床生物技术公司，随后与Crescent Biopharma，Inc.合并。他此前还曾在GlycoMimetics的董事会任职。自2023年10月起，Semerjian先生还担任生物技术创新组织的董事会成员。2020年6月至2021年7月，Semerjian先生在Emerge Bio Consulting担任独立的医疗保健顾问，就医疗保健投资项目为私募股权公司提供咨询。Semerjian先生曾担任Immunomedics Inc.的总裁兼首席执行官，该公司是一家专注于癌症治疗的抗体-药物偶联物的生物技术公司。在2018年3月至2020年4月被吉利德科学公司收购之前，从2020年4月至2020年5月，Semerjian先生曾担任IPSEN Pharma的执行副总裁兼首席商务官，该公司是一家全球性制药公司，专注于高度未满足的医疗需求领域，领导和执行IPSEN的全球商业战略和跨肿瘤学、神经科学和罕见疾病的职能。2017年2月至2018年2月，担任易卜生专科护理国际区域和全球特许经营权总裁兼负责人。从1994年到2017年1月，Semerjian先生在全球制药公司诺华制药担任过多个商业、营销和销售职位，责任越来越大，包括担任KISQALI的高级副总裁和全球发布负责人，在美国、中东和北非和北欧担任区域副总裁血液学和肿瘤学职务，并担任格列卫全球品牌总监，以及全球性制药公司默沙东和跨国化工与材料公司索尔维。Semerjian先生拥有加拿大康奈尔大学和皇后大学的MBA学位，以及黎巴嫩美国大学的生物学学士学位。董事会认为，Semerjian先生深厚的商业和血液学专业知识、广泛的领导经验和全球视野使他有资格担任董事会成员。
- Harout Semerjian,most recently served as President and Chief Executive Officer of GlycoMimetics, Inc., a late-stage clinical biotechnology company subsequently combined with Crescent Biopharma, Inc., from August 2021 until February 2025. He also previously served on the board of directors of GlycoMimetics. Since October 2023, Mr. Semerjian has also served as a member of the board of directors at the Biotechnology Innovation Organization. From June 2020 to July 2021, Mr. Semerjian served as an independent healthcare consultant at Emerge Bio Consulting, advising private equity firms on healthcare investment projects. Mr. Semerjian served as President and Chief Executive Officer of Immunomedics Inc., a biotechnology company specializing in antibody-drug conjugates for cancer treatment, from April 2020 to May 2020, prior to its acquisition by Gilead Sciences, Inc. From March 2018 to April 2020, Mr. Semerjian served as Executive Vice President, Chief Commercial Officer of Ipsen Pharma, a global, pharmaceutical company focusing on areas of high unmet medical need, leading and executing Ipsen's global commercial strategy and functions across oncology, neurosciences and rare diseases. From February 2017 to February 2018, he served as President and Head of Ipsen's Specialty Care International Region & Global Franchises. From 1994 to January 2017, Mr. Semerjian held several commercial, marketing and sales positions of increasing responsibility within Novartis Pharmaceuticals, a global pharmaceutical company, including serving as Senior Vice President and Global Launch Leader for KISQALI, in regional vice president hematology and oncology roles in the U.S., MENA and the Nordics, and as global brand director for Gleevec, as well as for Merck, a global pharmaceutical company, and Solvay, a multinational chemical and materials company. Mr. Semerjian holds an MBA from Cornell University and Queen's University in Canada, and a B.S. in Biology from Lebanese American University.
- John F. McDonald
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Robert J. Spiegel
-
Robert J. Spiegel于2015年1月成为Sucampo的董事。他是Spiegel Consulting，LLC的总裁兼创始人，自2012年以来一直担任威尔康奈尔医学中心的副教授。 Spiegel博士此前曾于2014年1月至2016年4月担任PTC Therapeutics，Inc.的首席医学官，并于1998年至2009年担任先灵-雅研究所的首席医学官，在1983年加入该公司后，他担任越来越重要的职务。目前担任私人生物技术公司NexImmune，Inc.和Vidac Pharma的董事长。他还自2013年8月起担任Edge Therapeutics，Inc.上市公司的董事会成员，自2010年5月起担任Geron Corporation的董事会成员，并担任许多生物技术公司的顾问。他还担任以色列生物技术基金和全球私募股权投资机构Warburg Pincus的顾问。他曾于2010年5月至2012年1月担任公开上市的生物技术公司Capstone Therapeutics Corp.的董事会成员，并于2010年7月担任公开上市的生物制药公司Talon Therapeutics的董事会成员，直到2013年7月被Spectrum Pharmaceuticals收购为止。收到他的学士学位在耶鲁大学获得博士学位，在宾夕法尼亚大学获得博士学位。
Robert J. Spiegel has served as a director of Geron since May 2010. Dr. Spiegel currently serves as an Associate Professor at the Weill Cornell Medical School, a Senior Advisor to Warburg Pincus, a private equity firm, and an Advisor to the Israel Biotech Fund, a venture investment fund. He is also a member of the board of directors of Ayala Pharmaceuticals, a clinical-stage oncology company, since December 2017; Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing targeted medicines for cancer and other proliferative diseases, since September 2018; Athenex, Inc., a global biopharmaceutical oncology company, since August 2020; and several privately-held biotechnology companies. He previously served as a director for Avior Computing Corporation, a privately-held governance risk and compliance process technology company, from October 2011 to November 2017; Talon Therapeutics, Inc., a biopharmaceutical company, from July 2010 to July 2013; Capstone Therapeutics Corp., a biotechnology company, from May 2010 to January 2012; Sucampo Pharmaceuticals, Inc., a biopharmaceutical company, from January 2015 to January 2018; and PDS Biotechnology Corporation formerly Edge Therapeutics, Inc., a biotechnology company, from August 2013 to March 2019; the Cancer Institute of New Jersey from 1999 to 2009; and Cancer Care New Jersey from 1995 to 2011. From March 2011 to April 2016 Dr. Spiegel served as Chief Medical Officer of PTC Therapeutics, Inc., a biopharmaceutical company focused on discovering and developing treatments for rare disorders. In 2009 after 26 years with the Schering-Plough Corporation (now Merck & Co.), a global healthcare company, Dr. Spiegel retired as Chief Medical Officer and Senior Vice President of the Schering-Plough Research Institute, the pharmaceutical research arm of the Schering-Plough Corporation. His career at Schering-Plough involved various positions, including Director of clinical research for oncology, Vice President of clinical research, and Senior Vice President of worldwide clinical research. Following a residency in internal medicine, Dr. Spiegel completed a fellowship in medical oncology at the National Cancer Institute, and from 1981 to 1999 he held academic positions at the National Cancer Institute and New York University Cancer Center. Dr. Spiegel holds a B.A. from Yale University and an M.D. from the University of Pennsylvania. - Robert J. Spiegel于2015年1月成为Sucampo的董事。他是Spiegel Consulting，LLC的总裁兼创始人，自2012年以来一直担任威尔康奈尔医学中心的副教授。 Spiegel博士此前曾于2014年1月至2016年4月担任PTC Therapeutics，Inc.的首席医学官，并于1998年至2009年担任先灵-雅研究所的首席医学官，在1983年加入该公司后，他担任越来越重要的职务。目前担任私人生物技术公司NexImmune，Inc.和Vidac Pharma的董事长。他还自2013年8月起担任Edge Therapeutics，Inc.上市公司的董事会成员，自2010年5月起担任Geron Corporation的董事会成员，并担任许多生物技术公司的顾问。他还担任以色列生物技术基金和全球私募股权投资机构Warburg Pincus的顾问。他曾于2010年5月至2012年1月担任公开上市的生物技术公司Capstone Therapeutics Corp.的董事会成员，并于2010年7月担任公开上市的生物制药公司Talon Therapeutics的董事会成员，直到2013年7月被Spectrum Pharmaceuticals收购为止。收到他的学士学位在耶鲁大学获得博士学位，在宾夕法尼亚大学获得博士学位。
- Robert J. Spiegel has served as a director of Geron since May 2010. Dr. Spiegel currently serves as an Associate Professor at the Weill Cornell Medical School, a Senior Advisor to Warburg Pincus, a private equity firm, and an Advisor to the Israel Biotech Fund, a venture investment fund. He is also a member of the board of directors of Ayala Pharmaceuticals, a clinical-stage oncology company, since December 2017; Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing targeted medicines for cancer and other proliferative diseases, since September 2018; Athenex, Inc., a global biopharmaceutical oncology company, since August 2020; and several privately-held biotechnology companies. He previously served as a director for Avior Computing Corporation, a privately-held governance risk and compliance process technology company, from October 2011 to November 2017; Talon Therapeutics, Inc., a biopharmaceutical company, from July 2010 to July 2013; Capstone Therapeutics Corp., a biotechnology company, from May 2010 to January 2012; Sucampo Pharmaceuticals, Inc., a biopharmaceutical company, from January 2015 to January 2018; and PDS Biotechnology Corporation formerly Edge Therapeutics, Inc., a biotechnology company, from August 2013 to March 2019; the Cancer Institute of New Jersey from 1999 to 2009; and Cancer Care New Jersey from 1995 to 2011. From March 2011 to April 2016 Dr. Spiegel served as Chief Medical Officer of PTC Therapeutics, Inc., a biopharmaceutical company focused on discovering and developing treatments for rare disorders. In 2009 after 26 years with the Schering-Plough Corporation (now Merck & Co.), a global healthcare company, Dr. Spiegel retired as Chief Medical Officer and Senior Vice President of the Schering-Plough Research Institute, the pharmaceutical research arm of the Schering-Plough Corporation. His career at Schering-Plough involved various positions, including Director of clinical research for oncology, Vice President of clinical research, and Senior Vice President of worldwide clinical research. Following a residency in internal medicine, Dr. Spiegel completed a fellowship in medical oncology at the National Cancer Institute, and from 1981 to 1999 he held academic positions at the National Cancer Institute and New York University Cancer Center. Dr. Spiegel holds a B.A. from Yale University and an M.D. from the University of Pennsylvania.
- V. Bryan Lawlis
-
V. Bryan Lawlis，2012年以来，他担任Geron董事。他目前担任一家专门从事罕见遗传病生物制药公司BioMarin Pharmaceuticals，一家专门从事治疗人类疾病定制抗体的生物制药公司KaloBios Pharmaceuticals和几个私营生物技术公司的董事。Lawlis博士是一家处于早期阶段，由他2006年联合建立私营生物技术公司Itero Biopharmaceuticals的总裁兼首席执行官。Lawlis 博士2004年8月起曾担任一家专注于药物投递技术的专门药品公司Aradigm Corporation的总裁兼首席执行官，也是2005年2月以来，担任它的董事会成员，这两个职位都一直担任到2006年8月。Lawlis博士2003年6月到2004年8月担任Aradigm Corporation的总裁兼首席运营官，2001年11月到2003年6月担任它的首席运营官。之前，Lawlis博士联合创立了一家合法生物制药制造公司Covance Biotechnology Services，并且1996年到1999年担任它的总裁兼首席执行官，1999年到2001年担任董事长，之后2001年它被卖给Akzo Nobel, NV的子公司Diosynth RTP。1981年到1996年，Lawlis博士受雇于Genencor和Genentech。他在Genentech的最后职位是工艺流程科学副总裁。Lawlis博士拥有得克萨斯大学奥斯汀分校微生物学专业学士学位，以及华盛顿州立大学生物化学专业博士学位。
V. Bryan Lawlis has served as a director of Geron since March 2012. He also serves as a member of the boards of directors of BioMarin Pharmaceutical, Inc., a biopharmaceutical company specializing in rare genetic diseases, since June 2007; Coherus BioSciences, Inc., a biologics platform company specializing in biosimilars, since May 2014; Aeglea BioTherapeutics, Inc., a biotechnology company specializing in human enzyme therapeutics for rare genetic diseases and cancer, since July 2018; and several privately-held biotechnology companies. In addition, he serves as an advisor to Phoenix Venture Partners, a venture capital firm specializing in manufacturing technologies, since October 2015. Dr. Lawlis previously served as a director of KaloBios Pharmaceuticals, Inc., a biopharmaceutical company, from August 2013 to September 2014; and Sutro Biopharma, Inc., a biologics platform company specializing in therapeutics for cancer and autoimmune disorders, from January 2004 to June 2019. Dr. Lawlis was the President and Chief Executive Officer of Itero Biopharmaceuticals LLC, a privately-held, early stage biopharmaceutical company that he co-founded, from 2006 to 2011. Dr. Lawlis also held several senior management positions in the biopharmaceutical industry, including President and Chief Executive Officer of Aradigm Corporation, a specialty drug company focused on drug delivery technologies, and President and Chief Executive Officer of Covance Biotechnology Services, a contract biopharmaceutical manufacturing operation, which he co-founded. Dr. Lawlis holds a B.A. in microbiology from the University of Texas at Austin and a Ph.D. in biochemistry from Washington State University. - V. Bryan Lawlis，2012年以来，他担任Geron董事。他目前担任一家专门从事罕见遗传病生物制药公司BioMarin Pharmaceuticals，一家专门从事治疗人类疾病定制抗体的生物制药公司KaloBios Pharmaceuticals和几个私营生物技术公司的董事。Lawlis博士是一家处于早期阶段，由他2006年联合建立私营生物技术公司Itero Biopharmaceuticals的总裁兼首席执行官。Lawlis 博士2004年8月起曾担任一家专注于药物投递技术的专门药品公司Aradigm Corporation的总裁兼首席执行官，也是2005年2月以来，担任它的董事会成员，这两个职位都一直担任到2006年8月。Lawlis博士2003年6月到2004年8月担任Aradigm Corporation的总裁兼首席运营官，2001年11月到2003年6月担任它的首席运营官。之前，Lawlis博士联合创立了一家合法生物制药制造公司Covance Biotechnology Services，并且1996年到1999年担任它的总裁兼首席执行官，1999年到2001年担任董事长，之后2001年它被卖给Akzo Nobel, NV的子公司Diosynth RTP。1981年到1996年，Lawlis博士受雇于Genencor和Genentech。他在Genentech的最后职位是工艺流程科学副总裁。Lawlis博士拥有得克萨斯大学奥斯汀分校微生物学专业学士学位，以及华盛顿州立大学生物化学专业博士学位。
- V. Bryan Lawlis has served as a director of Geron since March 2012. He also serves as a member of the boards of directors of BioMarin Pharmaceutical, Inc., a biopharmaceutical company specializing in rare genetic diseases, since June 2007; Coherus BioSciences, Inc., a biologics platform company specializing in biosimilars, since May 2014; Aeglea BioTherapeutics, Inc., a biotechnology company specializing in human enzyme therapeutics for rare genetic diseases and cancer, since July 2018; and several privately-held biotechnology companies. In addition, he serves as an advisor to Phoenix Venture Partners, a venture capital firm specializing in manufacturing technologies, since October 2015. Dr. Lawlis previously served as a director of KaloBios Pharmaceuticals, Inc., a biopharmaceutical company, from August 2013 to September 2014; and Sutro Biopharma, Inc., a biologics platform company specializing in therapeutics for cancer and autoimmune disorders, from January 2004 to June 2019. Dr. Lawlis was the President and Chief Executive Officer of Itero Biopharmaceuticals LLC, a privately-held, early stage biopharmaceutical company that he co-founded, from 2006 to 2011. Dr. Lawlis also held several senior management positions in the biopharmaceutical industry, including President and Chief Executive Officer of Aradigm Corporation, a specialty drug company focused on drug delivery technologies, and President and Chief Executive Officer of Covance Biotechnology Services, a contract biopharmaceutical manufacturing operation, which he co-founded. Dr. Lawlis holds a B.A. in microbiology from the University of Texas at Austin and a Ph.D. in biochemistry from Washington State University.
- Susan M. Molineaux
-
Susan M. Molineaux，2012年9月以来担任Geron董事。Calithera Biosciences是一家开发肿瘤治疗的私营生物技术公司，自从2010年6月联合建立这家公司以来，她担任公司的首席执行官兼总裁。在Calithera之前，Molineaux博士联合创立一家肿瘤为主导方向的生物制药公司Proteolix，并且2003年12月到2005年12月担任以及2009年2月到2009年11月担任首席科学官，2006年1月到2009年2月担任总裁兼首席执行官。Molineaux博士负责Proteolix第二代蛋白酶体抑制剂carfilzomib，现在市场上称为Kyprolis的开发，治疗多发性骨髓瘤，负责从发现到临床试验完成，加速获得批准，直到公司2009年11月被一家全球以肿瘤为主导方向的生物制药公司Onyx Pharmaceuticals收购。2000年到2003年，Molineaux博士担任一家专注炎症和自身免疫性疾病的生物制药公司Rigel Pharmaceuticals的生物副总裁。1999年到2000年以及1994年到1999年，她在一家肿瘤学为主导的生物制药公司Praecis Pharmaceuticals担任生物副总裁。1989年到1994年，她是一家制药公司默克的免疫学组的科学家。Molineaux博士拥有史密斯学院的生物学学士学位和约翰霍普金斯大学分子生物学的博士学位，也完成了哥伦比亚大学的博士后。她目前担任北加利福尼亚生命科学协会Bay Bio的主席，旧金山海岸数学科学研究项目We Teach Science董事会成员。
Susan M. Molineaux, Ph.D. has served as a director since April 2015. Dr. Molineaux has served as President, Chief Executive Officer and as a member of the board of directors of Calithera Biosciences, Inc. since she co-founded the biopharmaceutical company in March 2010. Dr. Molineaux co-founded Proteolix, Inc., a biopharmaceutical company, where she served as Chief Scientific Officer from 2003 to 2005 Chief Executive Officer from January 2006 to January 2009 and again as Chief Scientific Officer from February 2009 until Proteolix's acquisition by Onyx Pharmaceuticals, Inc. in November 2009. From 2000 to 2003 Dr. Molineaux served as Vice President of Biology at Rigel Pharmaceuticals, Inc., a drug development company. From 1999 to 2000 she served as Vice President of Biology at Praelux, Inc., a biopharmaceutical company, and from 1994 through 1999 she served as Vice President of Drug Development at Praecis Pharmaceuticals, Inc., a biopharmaceutical company. From 1989 until 1994 she was a scientist in the Immunology group at Merck & Co. Dr. Molineaux also serves as a member of the board of directors of Geron Corporation, a biopharmaceutical company and served as a member of the board of directors of the California Life Sciences Association until March 2016. In June 2017 Dr. Molineaux joined the board of trustees of Smith College and she also serves as on the board of directors of Cyteir Therapeutics, Inc., a privately held biotechnology company. She is also a Scientific Advisor at Lightstone Ventures. Dr. Molineaux holds a B.S. in Biology from Smith College and a Ph.D. in Molecular Biology from Johns Hopkins University, and she completed a postdoctoral fellowship at Columbia University. - Susan M. Molineaux，2012年9月以来担任Geron董事。Calithera Biosciences是一家开发肿瘤治疗的私营生物技术公司，自从2010年6月联合建立这家公司以来，她担任公司的首席执行官兼总裁。在Calithera之前，Molineaux博士联合创立一家肿瘤为主导方向的生物制药公司Proteolix，并且2003年12月到2005年12月担任以及2009年2月到2009年11月担任首席科学官，2006年1月到2009年2月担任总裁兼首席执行官。Molineaux博士负责Proteolix第二代蛋白酶体抑制剂carfilzomib，现在市场上称为Kyprolis的开发，治疗多发性骨髓瘤，负责从发现到临床试验完成，加速获得批准，直到公司2009年11月被一家全球以肿瘤为主导方向的生物制药公司Onyx Pharmaceuticals收购。2000年到2003年，Molineaux博士担任一家专注炎症和自身免疫性疾病的生物制药公司Rigel Pharmaceuticals的生物副总裁。1999年到2000年以及1994年到1999年，她在一家肿瘤学为主导的生物制药公司Praecis Pharmaceuticals担任生物副总裁。1989年到1994年，她是一家制药公司默克的免疫学组的科学家。Molineaux博士拥有史密斯学院的生物学学士学位和约翰霍普金斯大学分子生物学的博士学位，也完成了哥伦比亚大学的博士后。她目前担任北加利福尼亚生命科学协会Bay Bio的主席，旧金山海岸数学科学研究项目We Teach Science董事会成员。
- Susan M. Molineaux, Ph.D. has served as a director since April 2015. Dr. Molineaux has served as President, Chief Executive Officer and as a member of the board of directors of Calithera Biosciences, Inc. since she co-founded the biopharmaceutical company in March 2010. Dr. Molineaux co-founded Proteolix, Inc., a biopharmaceutical company, where she served as Chief Scientific Officer from 2003 to 2005 Chief Executive Officer from January 2006 to January 2009 and again as Chief Scientific Officer from February 2009 until Proteolix's acquisition by Onyx Pharmaceuticals, Inc. in November 2009. From 2000 to 2003 Dr. Molineaux served as Vice President of Biology at Rigel Pharmaceuticals, Inc., a drug development company. From 1999 to 2000 she served as Vice President of Biology at Praelux, Inc., a biopharmaceutical company, and from 1994 through 1999 she served as Vice President of Drug Development at Praecis Pharmaceuticals, Inc., a biopharmaceutical company. From 1989 until 1994 she was a scientist in the Immunology group at Merck & Co. Dr. Molineaux also serves as a member of the board of directors of Geron Corporation, a biopharmaceutical company and served as a member of the board of directors of the California Life Sciences Association until March 2016. In June 2017 Dr. Molineaux joined the board of trustees of Smith College and she also serves as on the board of directors of Cyteir Therapeutics, Inc., a privately held biotechnology company. She is also a Scientific Advisor at Lightstone Ventures. Dr. Molineaux holds a B.S. in Biology from Smith College and a Ph.D. in Molecular Biology from Johns Hopkins University, and she completed a postdoctoral fellowship at Columbia University.
高管简历
中英对照 | 中文 | 英文- Harout Semerjian
Harout Semerjian，最近于2021年8月至2025年2月担任GlycoMimetics，Inc.的总裁兼首席执行官，该公司是一家后期临床生物技术公司，随后与Crescent Biopharma，Inc.合并。他此前还曾在GlycoMimetics的董事会任职。自2023年10月起，Semerjian先生还担任生物技术创新组织的董事会成员。2020年6月至2021年7月，Semerjian先生在Emerge Bio Consulting担任独立的医疗保健顾问，就医疗保健投资项目为私募股权公司提供咨询。Semerjian先生曾担任Immunomedics Inc.的总裁兼首席执行官，该公司是一家专注于癌症治疗的抗体-药物偶联物的生物技术公司。在2018年3月至2020年4月被吉利德科学公司收购之前，从2020年4月至2020年5月，Semerjian先生曾担任IPSEN Pharma的执行副总裁兼首席商务官，该公司是一家全球性制药公司，专注于高度未满足的医疗需求领域，领导和执行IPSEN的全球商业战略和跨肿瘤学、神经科学和罕见疾病的职能。2017年2月至2018年2月，担任易卜生专科护理国际区域和全球特许经营权总裁兼负责人。从1994年到2017年1月，Semerjian先生在全球制药公司诺华制药担任过多个商业、营销和销售职位，责任越来越大，包括担任KISQALI的高级副总裁和全球发布负责人，在美国、中东和北非和北欧担任区域副总裁血液学和肿瘤学职务，并担任格列卫全球品牌总监，以及全球性制药公司默沙东和跨国化工与材料公司索尔维。Semerjian先生拥有加拿大康奈尔大学和皇后大学的MBA学位，以及黎巴嫩美国大学的生物学学士学位。董事会认为，Semerjian先生深厚的商业和血液学专业知识、广泛的领导经验和全球视野使他有资格担任董事会成员。
Harout Semerjian,most recently served as President and Chief Executive Officer of GlycoMimetics, Inc., a late-stage clinical biotechnology company subsequently combined with Crescent Biopharma, Inc., from August 2021 until February 2025. He also previously served on the board of directors of GlycoMimetics. Since October 2023, Mr. Semerjian has also served as a member of the board of directors at the Biotechnology Innovation Organization. From June 2020 to July 2021, Mr. Semerjian served as an independent healthcare consultant at Emerge Bio Consulting, advising private equity firms on healthcare investment projects. Mr. Semerjian served as President and Chief Executive Officer of Immunomedics Inc., a biotechnology company specializing in antibody-drug conjugates for cancer treatment, from April 2020 to May 2020, prior to its acquisition by Gilead Sciences, Inc. From March 2018 to April 2020, Mr. Semerjian served as Executive Vice President, Chief Commercial Officer of Ipsen Pharma, a global, pharmaceutical company focusing on areas of high unmet medical need, leading and executing Ipsen's global commercial strategy and functions across oncology, neurosciences and rare diseases. From February 2017 to February 2018, he served as President and Head of Ipsen's Specialty Care International Region & Global Franchises. From 1994 to January 2017, Mr. Semerjian held several commercial, marketing and sales positions of increasing responsibility within Novartis Pharmaceuticals, a global pharmaceutical company, including serving as Senior Vice President and Global Launch Leader for KISQALI, in regional vice president hematology and oncology roles in the U.S., MENA and the Nordics, and as global brand director for Gleevec, as well as for Merck, a global pharmaceutical company, and Solvay, a multinational chemical and materials company. Mr. Semerjian holds an MBA from Cornell University and Queen's University in Canada, and a B.S. in Biology from Lebanese American University.- Harout Semerjian，最近于2021年8月至2025年2月担任GlycoMimetics，Inc.的总裁兼首席执行官，该公司是一家后期临床生物技术公司，随后与Crescent Biopharma，Inc.合并。他此前还曾在GlycoMimetics的董事会任职。自2023年10月起，Semerjian先生还担任生物技术创新组织的董事会成员。2020年6月至2021年7月，Semerjian先生在Emerge Bio Consulting担任独立的医疗保健顾问，就医疗保健投资项目为私募股权公司提供咨询。Semerjian先生曾担任Immunomedics Inc.的总裁兼首席执行官，该公司是一家专注于癌症治疗的抗体-药物偶联物的生物技术公司。在2018年3月至2020年4月被吉利德科学公司收购之前，从2020年4月至2020年5月，Semerjian先生曾担任IPSEN Pharma的执行副总裁兼首席商务官，该公司是一家全球性制药公司，专注于高度未满足的医疗需求领域，领导和执行IPSEN的全球商业战略和跨肿瘤学、神经科学和罕见疾病的职能。2017年2月至2018年2月，担任易卜生专科护理国际区域和全球特许经营权总裁兼负责人。从1994年到2017年1月，Semerjian先生在全球制药公司诺华制药担任过多个商业、营销和销售职位，责任越来越大，包括担任KISQALI的高级副总裁和全球发布负责人，在美国、中东和北非和北欧担任区域副总裁血液学和肿瘤学职务，并担任格列卫全球品牌总监，以及全球性制药公司默沙东和跨国化工与材料公司索尔维。Semerjian先生拥有加拿大康奈尔大学和皇后大学的MBA学位，以及黎巴嫩美国大学的生物学学士学位。董事会认为，Semerjian先生深厚的商业和血液学专业知识、广泛的领导经验和全球视野使他有资格担任董事会成员。
- Harout Semerjian,most recently served as President and Chief Executive Officer of GlycoMimetics, Inc., a late-stage clinical biotechnology company subsequently combined with Crescent Biopharma, Inc., from August 2021 until February 2025. He also previously served on the board of directors of GlycoMimetics. Since October 2023, Mr. Semerjian has also served as a member of the board of directors at the Biotechnology Innovation Organization. From June 2020 to July 2021, Mr. Semerjian served as an independent healthcare consultant at Emerge Bio Consulting, advising private equity firms on healthcare investment projects. Mr. Semerjian served as President and Chief Executive Officer of Immunomedics Inc., a biotechnology company specializing in antibody-drug conjugates for cancer treatment, from April 2020 to May 2020, prior to its acquisition by Gilead Sciences, Inc. From March 2018 to April 2020, Mr. Semerjian served as Executive Vice President, Chief Commercial Officer of Ipsen Pharma, a global, pharmaceutical company focusing on areas of high unmet medical need, leading and executing Ipsen's global commercial strategy and functions across oncology, neurosciences and rare diseases. From February 2017 to February 2018, he served as President and Head of Ipsen's Specialty Care International Region & Global Franchises. From 1994 to January 2017, Mr. Semerjian held several commercial, marketing and sales positions of increasing responsibility within Novartis Pharmaceuticals, a global pharmaceutical company, including serving as Senior Vice President and Global Launch Leader for KISQALI, in regional vice president hematology and oncology roles in the U.S., MENA and the Nordics, and as global brand director for Gleevec, as well as for Merck, a global pharmaceutical company, and Solvay, a multinational chemical and materials company. Mr. Semerjian holds an MBA from Cornell University and Queen's University in Canada, and a B.S. in Biology from Lebanese American University.
- Shannon T. Odam
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Michelle J. Robertson
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Scott A. Samuels
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Edward E. Koval
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Faye Feller
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Joseph Emile Eid
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Melissa A. Kelly Behrs
Melissa A. Kelly Behrs，2012年9月以来担任Geron Corporation的投资组合和联盟管理的高级副总裁，之前2011年5月以来担任Geron Corporation的战略组合投资管理和产品开发制造的高级副总裁。2007年1月到2011年5月，她担任医疗开发和肿瘤学高级副总裁。2002年4月到2003年1月，Behrs女士担任Geron Corporation的企业开发副总裁。2001年4月到2002年4月，Behrs女士担任Geron Corporation的项目和开发技术总经理。Behrs女士1998年11月加入Geron Corporation，担任企业开发董事。1990年到1998年，Behrs女士在一家生物技术项目和开发公司Genetics工作，期初担任助理财务总监，之后担任临床运营副董事，负责临床运营方面的所有商业开发、监管和项目管理活动。Behrs女士拥有波士顿学院的学士学位和巴布森学院的MBA学位。
Melissa A. Kelly Behrs has served as Geron Corporation Executive Vice President, Chief Business Officer since January 2019. Previously, she was Geron Corporation Executive Vice President, Business Development and Portfolio & Alliance Management Ms. Behrs joined Geron in November 1998 as Director of Corporate Development. Since then, she has also served in various managerial positions, including General Manager, R&D Technologies; Vice President, Corporate Development; Senior Vice President, Therapeutic Development, Oncology; and Senior Vice President, Strategic Portfolio Management. From 1990 to 1998 Ms. Behrs worked at Genetics Institute, Inc., a biotechnology research and development company, serving initially as Assistant Treasurer and then as Associate Director of Preclinical Operations where she was responsible for all business development, regulatory, and project management activities for the Preclinical Development function. Ms. Behrs received a B.S. from Boston College and an M.B.A. from Babson College.- Melissa A. Kelly Behrs，2012年9月以来担任Geron Corporation的投资组合和联盟管理的高级副总裁，之前2011年5月以来担任Geron Corporation的战略组合投资管理和产品开发制造的高级副总裁。2007年1月到2011年5月，她担任医疗开发和肿瘤学高级副总裁。2002年4月到2003年1月，Behrs女士担任Geron Corporation的企业开发副总裁。2001年4月到2002年4月，Behrs女士担任Geron Corporation的项目和开发技术总经理。Behrs女士1998年11月加入Geron Corporation，担任企业开发董事。1990年到1998年，Behrs女士在一家生物技术项目和开发公司Genetics工作，期初担任助理财务总监，之后担任临床运营副董事，负责临床运营方面的所有商业开发、监管和项目管理活动。Behrs女士拥有波士顿学院的学士学位和巴布森学院的MBA学位。
- Melissa A. Kelly Behrs has served as Geron Corporation Executive Vice President, Chief Business Officer since January 2019. Previously, she was Geron Corporation Executive Vice President, Business Development and Portfolio & Alliance Management Ms. Behrs joined Geron in November 1998 as Director of Corporate Development. Since then, she has also served in various managerial positions, including General Manager, R&D Technologies; Vice President, Corporate Development; Senior Vice President, Therapeutic Development, Oncology; and Senior Vice President, Strategic Portfolio Management. From 1990 to 1998 Ms. Behrs worked at Genetics Institute, Inc., a biotechnology research and development company, serving initially as Assistant Treasurer and then as Associate Director of Preclinical Operations where she was responsible for all business development, regulatory, and project management activities for the Preclinical Development function. Ms. Behrs received a B.S. from Boston College and an M.B.A. from Babson College.